Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felipe Ades

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Breast (Edinburgh, Scotland)|October 1, 2013
Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapiesAna Catarina Pinto, Felipe Ades, Evandro de Azambuja, et al.
Plos One|March 27, 2018
Correction: Prime incision: A minimally invasive approach to breast cancer surgical treatment-A 2 cohort retrospective comparison with conventional breast conserving surgerySilvio Eduardo Bromberg, Patricia Rodrigues Alves de Figueiredo Moraes, Felipe Ades
Plos One|March 15, 2017
Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USAFelipe Ades, Christelle Senterre, Dimitrios Zardavas, et al.
Revista Brasileira De Terapia Intensiva|October 14, 2014
[Poisoning syndrome due to 2,000 stings of africanized honeybees]Rita Vianna de Azevedo, Roberto Bueno de Paiva, Felipe Ades, et al.
Breast (Edinburgh, Scotland)|May 6, 2014
Cardiotoxicity of systemic agents used in breast cancerFelipe Ades, Dimitrios Zardavas, Ana Catarina Pinto, et al.
Revista Brasileira De Terapia Intensiva|October 14, 2014
[Macrophage migration inhibitory factor and interleukin-6 in crush syndrome: analogy with severity? Case reports]Rita C Vianna de Azevedo, Roberto Bueno de Paiva, Felipe Ades, et al.
Future Oncology (London, England)|March 28, 2023
Neoadjuvant treatment and survival outcomes by pathologic complete response in HER2-negative early breast cancersAmanda Crosbie, Trong Kim Le, Ying Zhang, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab caseFelipe Ades, Chistelle Senterre, Dimitrios Zardavas, et al.
Ecancermedicalscience|February 28, 2020
VUS-type alteration in POLD1 and microsatellite instability in a metastatic luminal B breast cancer patientCatarina Marchon da Silva, Denis Shimba, Denise Oishi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2014
Luminal B breast cancer: molecular characterization, clinical management, and future perspectivesFelipe Ades, Dimitrios Zardavas, Ivana Bozovic-Spasojevic, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Breast (Edinburgh, Scotland)|October 1, 2013
Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapiesAna Catarina Pinto, Felipe Ades, Evandro de Azambuja, et al.
Plos One|March 27, 2018
Correction: Prime incision: A minimally invasive approach to breast cancer surgical treatment-A 2 cohort retrospective comparison with conventional breast conserving surgerySilvio Eduardo Bromberg, Patricia Rodrigues Alves de Figueiredo Moraes, Felipe Ades
Plos One|March 15, 2017
Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USAFelipe Ades, Christelle Senterre, Dimitrios Zardavas, et al.
Revista Brasileira De Terapia Intensiva|October 14, 2014
[Poisoning syndrome due to 2,000 stings of africanized honeybees]Rita Vianna de Azevedo, Roberto Bueno de Paiva, Felipe Ades, et al.
Breast (Edinburgh, Scotland)|May 6, 2014
Cardiotoxicity of systemic agents used in breast cancerFelipe Ades, Dimitrios Zardavas, Ana Catarina Pinto, et al.
Revista Brasileira De Terapia Intensiva|October 14, 2014
[Macrophage migration inhibitory factor and interleukin-6 in crush syndrome: analogy with severity? Case reports]Rita C Vianna de Azevedo, Roberto Bueno de Paiva, Felipe Ades, et al.
Future Oncology (London, England)|March 28, 2023
Neoadjuvant treatment and survival outcomes by pathologic complete response in HER2-negative early breast cancersAmanda Crosbie, Trong Kim Le, Ying Zhang, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab caseFelipe Ades, Chistelle Senterre, Dimitrios Zardavas, et al.
Ecancermedicalscience|February 28, 2020
VUS-type alteration in POLD1 and microsatellite instability in a metastatic luminal B breast cancer patientCatarina Marchon da Silva, Denis Shimba, Denise Oishi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2014
Luminal B breast cancer: molecular characterization, clinical management, and future perspectivesFelipe Ades, Dimitrios Zardavas, Ivana Bozovic-Spasojevic, et al.
Pageof 3